Market Place
Sourcing Support
Ariceum Presents Data On 225Ac-Satoreotide At EANM 2024
22 Oct 2024 //
PR NEWSWIRE
Ariceum Begins Phase 1 Trial In Recurrent Glioblastoma Patients
25 Jul 2024 //
PR NEWSWIRE
Ariceum Preclinical Data Highlights At SNMMI 2024 Annual Meeting
10 Jun 2024 //
PR NEWSWIRE
Ariceum to present new radioligand therapy data at AACR Annual Meeting 2024
04 Apr 2024 //
PR NEWSWIRE
Ariceum Therapeutics announces opening of new state-of-the-art laboratory
05 Mar 2024 //
PR NEWSWIRE
Ariceum Granted UK Authorisation to Conduct Phase I Study of Iodine-123
29 Feb 2024 //
PR NEWSWIRE
Ariceum unveils early efficacy signal for lead asset in neuroendocrine cancers
28 Sep 2023 //
ENDPTS
Ariceum Therapeutics doses first patient with satoreotide in its Phase Ib study
07 Sep 2023 //
PR NEWSWIRE
Ariceum bolsters radiopharma efforts with Theragnostics buy
01 Jun 2023 //
FIERCE BIOTECH
Ariceum Therapeutics Expands Pipeline with Acquisition of Theragnostics Ltd
01 Jun 2023 //
PR NEWSWIRE
Ariceum and UCB to seek therapies for immune-related diseases and cancer
11 May 2023 //
PHARMACEUTICAL TECHNOLOGY
UCB and Ariceum sign a Strategic Research Collab to Discover New Modalities
10 May 2023 //
PR NEWSWIRE
Ariceum and AmbioPharm Enter Strategic Manufacturing & Supply Partnership
27 Oct 2022 //
PRESS RELEASE
Ariceum Therapeutics Appoints Chief Business Officer
07 Jul 2022 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.